{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T10:06:16Z","timestamp":1781085976220,"version":"3.54.1"},"reference-count":27,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2005,11,30]],"date-time":"2005-11-30T00:00:00Z","timestamp":1133308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2005,12]]},"abstract":"<jats:p>The increasing use of botulinum toxin type\u2010A, especially for focal dystonia and spasticity has highlighted the issue of secondary non\u2010responsiveness. Within the last few years botulinum toxin type\u2010B (Myobloc<jats:sup>\u00ae<\/jats:sup>\/Neurobloc<jats:sup>\u00ae<\/jats:sup>) has become commercially available as an alternative to type\u2010A. This paper discusses our initial experience of botulinum toxin type\u2010B in a total of 63 individuals who attended our botulinum clinic. Thirty\u2010six patients had cervical dystonia and a secondary non\u2010response to type\u2010A toxin. Thirteen of these patients (36%) had a reasonable clinical response to Neurobloc<jats:sup>\u00ae<\/jats:sup> and continue to have injections. The other 23 patients either had no response, or a poor response, or had unacceptable side effects and ceased treatment. A small number of people with blepharospasm, hemifacial spasm and foot dystonia also had a disappointing response to injection. Twenty patients with spasticity were also type\u2010A resistant. Seven of these show some continuing response to type\u2010B, without unacceptable side effects. These findings demonstrate that botulinum toxin type\u2010B has a place in the management of patients who have become non\u2010responsive to type\u2010A, but overall the responses to type\u2010B toxin were disappointing.<\/jats:p>","DOI":"10.1111\/j.1468-1331.2005.01095.x","type":"journal-article","created":{"date-parts":[[2005,11,30]],"date-time":"2005-11-30T23:51:16Z","timestamp":1133394676000},"page":"947-955","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["The use of botulinum toxin type\u2010B in the treatment of patients who have become unresponsive to botulinum toxin type\u2010A \u2013 initial experiences"],"prefix":"10.1111","volume":"12","author":[{"given":"M. P.","family":"Barnes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Best","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Kidd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Stark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Weeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Whitaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,11,30]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1177\/014107689208500906","article-title":"Botulinum toxin treatment of spasmodic torticollis","volume":"85","author":"Anderson TJ","year":"1992","journal-title":"J R Soc Med"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.10.12.2191"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.7.1439"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/apmr.2003.50070"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4598(1997)6 <146::AID-MUS10>3.0.CO;2-4"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.7.1431"},{"key":"e_1_2_5_8_1","first-page":"151","article-title":"News in botulinum toxin therapy. From dystonia to prophylactic treatment of migraine","volume":"20","author":"Ceballos\u2010Baumann AO","year":"2001","journal-title":"Nervenheilkunde"},{"key":"e_1_2_5_9_1","first-page":"R16","article-title":"Botulinum neurotoxin B in blepharospasm","volume":"365","author":"Colosimo C","year":"2002","journal-title":"NS Arch Pharmacol"},{"key":"e_1_2_5_10_1","first-page":"R18","article-title":"Botulinum toxin type\u2010B (Neurobloc\u00ae) in patients with botulinum toxin type A antibody\u2010induced therapy failure","volume":"365","author":"Dressler D","year":"2002","journal-title":"NS Arch Pharmacol"},{"key":"e_1_2_5_11_1","first-page":"82","article-title":"Botulinum toxin A antibodies in initial and delayed resistance to botulinum toxin A therapy in cervical dystonia","volume":"10","author":"Duane DD","year":"1995","journal-title":"Mov Disord"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870090216"},{"key":"e_1_2_5_13_1","first-page":"R20","article-title":"Botulinum toxin type\u2010B improves spasticity and function in patient with quadriplegia","volume":"365","author":"Guy W","year":"2002","journal-title":"NS Arch Pharmacol"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.304.6832.959-a"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1991.00530240057020"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.45.9.1743"},{"key":"e_1_2_5_17_1","first-page":"368","article-title":"Botulinum toxin treatment of essential tremor","volume":"10","author":"Jankovic J","year":"1995","journal-title":"Mov Disord"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870120116"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004150050345"},{"key":"e_1_2_5_20_1","first-page":"S29","article-title":"The safety and efficacy of botulinum toxin type\u2010B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials","volume":"55","author":"Lew MF","year":"2000","journal-title":"Neurology"},{"key":"e_1_2_5_21_1","volume-title":"Handbook of Botulinum Toxin Treatment","author":"Moore AP","year":"2003"},{"key":"e_1_2_5_22_1","first-page":"R32","article-title":"Botulinum toxin type\u2010B (BoNT\u2010B) for limb spasticity","volume":"365","author":"O'Brien C","year":"2002","journal-title":"NS Arch Pharmacol"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1191\/026921599677595404"},{"key":"e_1_2_5_24_1","first-page":"R44","article-title":"Efficacy of botulinum toxin type\u2010B (MyoblocTM) for treatment of blepharospasm: report of two cases","volume":"365","author":"Stacy M","year":"2002","journal-title":"NS Arch Pharmacol"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870120526"},{"key":"e_1_2_5_26_1","first-page":"181","article-title":"Production of circulating antibodies to botulinum\u2010A toxin in patients receiving repeated injections for dystonia","volume":"23","author":"Tsui JK","year":"1988","journal-title":"Ann Neurol"},{"key":"e_1_2_5_27_1","volume-title":"Measurement in Neurological Rehabilitation","author":"Wade DT","year":"1992"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.9.1715"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1331.2005.01095.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1331.2005.01095.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T16:57:34Z","timestamp":1696870654000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1331.2005.01095.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11,30]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["10.1111\/j.1468-1331.2005.01095.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1331.2005.01095.x","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11,30]]},"assertion":[{"value":"2005-11-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}